September 4, 2014 | NeuroDerm, a clinical-stage pharmaceutical company developing drugs for neurodegenerative diseases, announced the success of a Phase IIa clinical trial of their drug for Parkinson’s disease. Patients with serious to severe Parkinson’s disease were given the company’s ND0612H drug formulation that is continuously delivered through a belt pump. This solution suits severe cases of Parkinson’s disease that would normally require surgical procedures, instead administering drugs through a belt. The study was supported by a grant from The Michael J. Fox Foundation for Parkinson’s Research, with the final results of the trial expected in the fourth quarter of 2014.